Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oncolytic adenovirus expressing TGF-beta blocker + IFN-gamma
- Development stage
- Preclinical
- Lead developer
- University of Minnesota
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Administration
- Intratumoral
01
Overview
An unnamed, preclinical **replication-competent oncolytic adenovirus** engineered to locally express a transforming growth factor-beta blocker and interferon-gamma. The vector is being investigated by the University of Minnesota as an intratumoral viro-immunotherapy for pancreatic ductal adenocarcinoma. It is intended to combine adenovirus-mediated tumor-cell lysis with reversal of TGF-beta-associated immunosuppression and fibrosis, plus IFN-gamma-driven immune activation. In mouse pancreatic cancer models, the dual-transgene vector produced greater antitumor activity than single-transgene constructs, induced immune-cell infiltration, reduced fibrosis, generated abscopal activity, and enhanced responses when combined with CAR-T cells.
- Other names
- armed oncolytic adenovirus expressing TGF-beta blocker + IFN-gammaoncolytic adenovirus expressing TGF-beta blocker + IFN-gamma
02
Targets
TGFB1 (Transforming growth factor Beta-1 proprotein)TGFB3 (Transforming growth factor beta 3)CXADR (Coxsackievirus and adenovirus receptor)TGFB2 (Transforming growth factor beta 2)ITGAV (Integrin αV)IFNGR1 (Interferon gamma receptor 1)
Beyond the preview
Go deeper on oncolytic adenovirus expressing TGF-beta blocker + IFN-gamma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oncolytic adenovirus expressing TGF-beta blocker + IFN-gamma.